Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Filtrar resultados de búsqueda
Seleccionar modelos de datos

Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

27 Resultados de la búsqueda.

Eligibility Inflammatory Arthritis NCT00808496

- 7/5/18 - 1 formulario, 2 itemgroups, 15 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

The Effect of Biannual Monitoring With Magnetic Resonance Imaging (MRI), X-ray, or Usual Care on Treatment for Inflammatory Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00808496

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Screen - Chest X-Ray; Tender Joint Count; Swollen Joint Count; Electronically Transferred Lab Data; ESR

- 17/3/20 - 1 formulario, 11 itemgroups, 33 items, 1 idioma

Itemgroups: Chest X-Ray, Tender Joint Count Page 1, Tender Joint Count Page 2 , Joint Assessor Initials - Joint Pain/Tenderness , Calculations - Joint Pain/Tenderness, Swollen Joint Count Page 1, Swollen Joint Count Page 2, Joint Assessor Initials - Joint Swelling , Calculations - Joint Swelling , Electronically Transferred Lab Data, ESR - Local Laboratory

Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Eligibility Rheumatoid Arthritis NCT01029613

- 9/10/18 - 1 formulario, 2 itemgroups, 19 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers; ODM derived from: https://clinicaltrials.gov/show/NCT01029613

Eligibility Polyarticular-course Juvenile Idiopathic Arthritis (JIA) NCT01550003

- 22/1/21 - 1 formulario, 2 itemgroups, 17 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Pediatric Arthritis Study of Certolizumab Pegol; ODM derived from: https://clinicaltrials.gov/show/NCT01550003

MRT SHIP-START-3 Rheuma

- 3/7/21 - 1 formulario, 1 itemgroup, 1 item, 2 idiomas

Itemgroup: Rheuma

Rheuma form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name SHIP.SHIP3.MRT.MRTASS.MRTRHEUMA. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617 The English version of this form is under development.

Eligibility Rheumatoid Arthritis NCT00361634

- 17/6/17 - 1 formulario, 2 itemgroups, 12 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00361634

Verlaufsdoku KIRHE UKM University Hospital Muenster (UKM) Subform

- 22/11/16 - 1 formulario, 5 itemgroups, 24 items, 1 idioma

Itemgroups: Verlaufsdokumentation, Previous Medication, New Medication, Other Therapies, Physical Examination

Hospital Routine Documentation Subform at the University Hospital Muenster. Original Form name: Verlaufsdoku KIRHE UKM

Eligibility Systemic Juvenile Idiopathic Arthritis (SJIA) NCT02296424

- 12/7/19 - 1 formulario, 2 itemgroups, 16 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab; ODM derived from: https://clinicaltrials.gov/show/NCT02296424

Tocilizumab and non-biological DMARD in Rheumatoid Arthritis NCT01034397 - Eligibility Criteria

- 21/5/19 - 1 formulario, 2 itemgroups, 10 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs; ODM derived from: https://clinicaltrials.gov/show/NCT01034397

Eligibility Juvenile Idiopathic Arthritis NCT02277444

- 23/4/19 - 1 formulario, 2 itemgroups, 10 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02277444

Eligibility Juvenile Idiopathic Arthritis NCT01434082

- 29/4/20 - 1 formulario, 2 itemgroups, 14 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01434082

Eligibility Rheumatoid Arthritis NCT00484809

- 13/12/16 - 1 formulario, 2 itemgroups, 13 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children; ODM derived from: https://clinicaltrials.gov/show/NCT00484809

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.